GRI Bio Inc's stock price fell by 6.95% as it hit a 5-day low amid broader market gains.
The company received shareholder approval for a 1-for-28 reverse stock split, set to take effect on January 23, 2026, reducing outstanding shares from approximately 15.02 million to about 540,000. This move aims to enhance the stock price to meet Nasdaq listing requirements. However, the market reacted cautiously, with the stock price dropping by 4.21% following the announcement, indicating potential concerns about short-term performance and investor sentiment. Additionally, GRI Bio announced an $8 million public offering to support future operational needs, although the reverse stock split may affect financing terms.
The reverse stock split is a strategic move to improve the stock's market perception, but the immediate market reaction suggests that investors are wary of the implications for the company's future.
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 23.00 USD with a low forecast of 10.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 23.00 USD with a low forecast of 10.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.320
Low
10.00
Averages
23.00
High
36.00
Current: 5.320
Low
10.00
Averages
23.00
High
36.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$10
2025-04-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10
AI Analysis
2025-04-14
Reiterates
Strong Buy
Reason
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
